A randomised, double-blind, placebo-controlled trial evaluating the efficacy of prophylactic dexamethasone in preventing the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma found it to be more effective than a placebo regimen.
While further refining where radioembolization should optimally lie in current treatment paradigms for the most common liver-confined or liver-dominant cancers is important, a honing of current administration protocols is also possible, writes Suvranu Ganguli, Boston, USA.
A retrospective review of single-institution experience, published in July in the Journal of Vascular and Interventional Radiology (JVIR), suggests that percutaneous image-guided ablation is feasible, well tolerated and achieves “acceptable” local tumour control rates.
The US FDA has approved the investigational device exemption (IDE) study to evaluate the safety and efficacy of IN.PACT AV access drug-coated balloon as a treatment for failing arteriovenous fistulas in end-stage renal disease patients.
Gore has announced the first patient implant of conformable thoracic stent graft with Active Control System after receiving CE mark last month. The first implant was performed by Giovanni Torsello and Martin Austermann at St. Franziskus Hospital, Munster, Germany. The new device will be formally launched in European regions later this year.
The Gore Viatorr TIPS endoprosthesis with Controlled Expansion, a new device configuration developed by Gore, may reduce portal hypertension treatment complications, even when compared to the Gore Viatorr TIPS endoprosthesis, Gore’s legacy TIPS device. The latter has a strong history of patency and proven performance at fixed diameters. These findings were obtained from the abstract presented at The International Liver Congress 2017 in Amsterdam.
The Montpellier University Hospital (Montpellier, France) has inaugurated an avant-garde interventional radiology intervention room in the Department of Interventional Radiology at the St-Eloi Hospital.
Medtronic has announced recent reimbursement approvals in both France and Belgium.
Johnson and Johnson Medical Devices Companies introduced Cerenovus, its new neurovascular business, at the Society of NeuroInterventional Surgery 14th Annual Meeting (SNIS; 24–28 July, Colorado Springs, USA).
The Journal of Vascular and Interventional Radiology’s (JVIR’s) impact factor—one measure of a journal’s influence based on the number of article citations compared to the total number of articles published—increased by 8.2% in 2016.
The 24-month results of the worldwide experience with Lutonix 035 drug-coated balloon (CR Bard/Beckton Dickenson) were published online in August in JACC: Cardiovascular Interventions. Data revealed that patients with femoropopliteal lesions who were treated with the drug-coated balloon experienced symptom improvement and that low reintervention rates were observed at 24 months, even in patients with difficult-to-treat lesions.
Merit Medical will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij to deliver the next generation in educational opportunities for interventional cardiologists and interventional radiologists. Kiemeneij will serve as a co-proctor at the upcoming Advanced Transradial Intervention Education Course for Interventional Cardiologists (13–14 October, Merit Medical Education Cente, Salt Lake City, USA).
Medtronic has announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting in Barcelona, Spain and published simultaneously in The Lancet.
A new study is underway at Emory Healthcare, Atlanta, USA, to evaluate the use of cryoablation to treat mild to moderate obesity.
Royal Philips has announced the acquisition of CardioProlific Inc, a USA-based, privately-held company that is developing catheter-based thrombectomy approaches to treat peripheral vascular disease. Financial details of the transaction will not be disclosed.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos